Overview

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children

Status:
Completed
Trial end date:
2018-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to select the optimal formulation of the norovirus vaccine from different concentrations of virus-like particles (VLP) combined with aluminum hydroxide for further development in children.
Phase:
Phase 2
Details
Lead Sponsor:
Takeda
Treatments:
Aluminum Hydroxide
Vaccines